INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Recruiting

Phase 2

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Sponsor:

Patrick Wen, MD

Code:

NCT02977780

Conditions

Glioblastoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Temozolomide

Neratinib

QBS10072S

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Patrick Wen, MD on 2024-10-17.